JP2018518153A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018518153A5 JP2018518153A5 JP2017552899A JP2017552899A JP2018518153A5 JP 2018518153 A5 JP2018518153 A5 JP 2018518153A5 JP 2017552899 A JP2017552899 A JP 2017552899A JP 2017552899 A JP2017552899 A JP 2017552899A JP 2018518153 A5 JP2018518153 A5 JP 2018518153A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- binding fragment
- antigen
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021200631A JP7456989B2 (ja) | 2015-04-07 | 2021-12-10 | デュシェンヌ型筋ジストロフィーの治療における抗ｆｌｔ－１抗体 |
| JP2024039804A JP7741225B2 (ja) | 2015-04-07 | 2024-03-14 | デュシェンヌ型筋ジストロフィーの治療における抗ｆｌｔ－１抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562144251P | 2015-04-07 | 2015-04-07 | |
| US62/144,251 | 2015-04-07 | ||
| US201662307645P | 2016-03-14 | 2016-03-14 | |
| US62/307,645 | 2016-03-14 | ||
| PCT/US2016/026352 WO2016164528A1 (en) | 2015-04-07 | 2016-04-07 | Anti-flt-1 antibodies for treating duchenne muscular dystrophy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021200631A Division JP7456989B2 (ja) | 2015-04-07 | 2021-12-10 | デュシェンヌ型筋ジストロフィーの治療における抗ｆｌｔ－１抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018518153A JP2018518153A (ja) | 2018-07-12 |
| JP2018518153A5 true JP2018518153A5 (enExample) | 2019-05-16 |
| JP6993880B2 JP6993880B2 (ja) | 2022-01-14 |
Family
ID=55754471
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017552899A Active JP6993880B2 (ja) | 2015-04-07 | 2016-04-07 | デュシェンヌ型筋ジストロフィーの治療における抗ｆｌｔ－１抗体 |
| JP2021200631A Active JP7456989B2 (ja) | 2015-04-07 | 2021-12-10 | デュシェンヌ型筋ジストロフィーの治療における抗ｆｌｔ－１抗体 |
| JP2024039804A Active JP7741225B2 (ja) | 2015-04-07 | 2024-03-14 | デュシェンヌ型筋ジストロフィーの治療における抗ｆｌｔ－１抗体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021200631A Active JP7456989B2 (ja) | 2015-04-07 | 2021-12-10 | デュシェンヌ型筋ジストロフィーの治療における抗ｆｌｔ－１抗体 |
| JP2024039804A Active JP7741225B2 (ja) | 2015-04-07 | 2024-03-14 | デュシェンヌ型筋ジストロフィーの治療における抗ｆｌｔ－１抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US10787515B2 (enExample) |
| EP (2) | EP4056593A1 (enExample) |
| JP (3) | JP6993880B2 (enExample) |
| CN (3) | CN120290577A (enExample) |
| AU (2) | AU2016246722B2 (enExample) |
| CA (1) | CA2981954A1 (enExample) |
| ES (1) | ES2910783T3 (enExample) |
| MA (1) | MA41899A (enExample) |
| MX (1) | MX2017012828A (enExample) |
| PL (1) | PL3280734T3 (enExample) |
| WO (1) | WO2016164528A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41899A (fr) | 2015-04-07 | 2018-02-13 | Shire Human Genetic Therapies | Anticorps anti-flt-1 pour traiter la dystrophie musculaire de duchenne |
| JP2022513693A (ja) * | 2018-11-29 | 2022-02-09 | ハーバー・バイオメド・セラピューティクス・リミテッド | 抗ｐｄ－ｌ１抗体製剤 |
| PH12022550211A1 (en) * | 2019-08-02 | 2022-12-12 | Cttq Akeso Shanghai Biomed Tech Co Ltd | Anti-pd-1 antibody and medical use thereof |
| CN114230666B (zh) * | 2021-12-20 | 2022-09-02 | 南京诺唯赞生物科技股份有限公司 | 一种t7 rna聚合酶的单克隆抗体及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8287864B2 (en) * | 2002-02-14 | 2012-10-16 | Immunomedics, Inc. | Structural variants of antibodies for improved therapeutic characteristics |
| CN102397542B (zh) | 2004-11-18 | 2014-05-07 | 英克隆有限责任公司 | 抗血管内皮生长因子受体-1的抗体 |
| CN102307902B (zh) | 2008-12-10 | 2016-02-24 | 埃博灵克斯股份有限公司 | 用于治疗与血管发生相关的疾病和病症的针对血管生成素/Tie系统的氨基酸序列和包括其的多肽 |
| WO2012109282A2 (en) | 2011-02-07 | 2012-08-16 | Agamin Pharmaceuticals, Llc | Methods and systems for treating or preventing pregnancy-related hypertensive disorders |
| CA2898998C (en) * | 2013-01-28 | 2023-02-14 | Regents Of The University Of Minnesota | Anti-flt-1 antibodies in treating duchenne muscular dystrophy |
| TW201517916A (zh) * | 2013-03-15 | 2015-05-16 | Lilly Co Eli | Ｖｅｇｆｒ１抗體之治療用途 |
| MA41899A (fr) | 2015-04-07 | 2018-02-13 | Shire Human Genetic Therapies | Anticorps anti-flt-1 pour traiter la dystrophie musculaire de duchenne |
-
2016
- 2016-04-06 MA MA041899A patent/MA41899A/fr unknown
- 2016-04-07 CN CN202510178279.0A patent/CN120290577A/zh active Pending
- 2016-04-07 WO PCT/US2016/026352 patent/WO2016164528A1/en not_active Ceased
- 2016-04-07 CN CN202210037246.0A patent/CN114539408B/zh active Active
- 2016-04-07 US US15/564,976 patent/US10787515B2/en active Active
- 2016-04-07 EP EP22153298.9A patent/EP4056593A1/en active Pending
- 2016-04-07 CA CA2981954A patent/CA2981954A1/en active Pending
- 2016-04-07 ES ES16716795T patent/ES2910783T3/es active Active
- 2016-04-07 PL PL16716795T patent/PL3280734T3/pl unknown
- 2016-04-07 JP JP2017552899A patent/JP6993880B2/ja active Active
- 2016-04-07 CN CN201680032814.0A patent/CN107787330B/zh active Active
- 2016-04-07 MX MX2017012828A patent/MX2017012828A/es unknown
- 2016-04-07 EP EP16716795.6A patent/EP3280734B1/en active Active
- 2016-04-07 AU AU2016246722A patent/AU2016246722B2/en active Active
-
2020
- 2020-08-12 US US16/991,762 patent/US20210206860A1/en not_active Abandoned
-
2021
- 2021-12-10 JP JP2021200631A patent/JP7456989B2/ja active Active
-
2022
- 2022-01-25 AU AU2022200466A patent/AU2022200466B2/en active Active
-
2023
- 2023-03-23 US US18/189,065 patent/US12435146B2/en active Active
-
2024
- 2024-03-14 JP JP2024039804A patent/JP7741225B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019205936B2 (en) | Methods for treating IL-6 mediated inflammation without immunosuppression | |
| JP2018510617A5 (enExample) | ||
| JP2014158469A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2019513726A5 (enExample) | ||
| US12312400B2 (en) | Engineered anti-il-2 antibodies | |
| JP2016519650A5 (enExample) | ||
| CN110799543A (zh) | 肝细胞癌的免疫治疗 | |
| JP2013544078A5 (enExample) | ||
| JP2015506945A5 (enExample) | ||
| JP2016505546A5 (enExample) | ||
| JP2018518153A5 (enExample) | ||
| JP2018536632A5 (ja) | Ｂ７‐ｈ３に特異的に結合する分子及びｐｄ‐１に特異的に結合する分子 | |
| CN112351794A (zh) | 用于尿路上皮癌的免疫治疗方法 | |
| JP2023504531A (ja) | 腫瘍治療のための二重特異性融合タンパク質と抗Ｈｅｒ２抗体の組合せ | |
| JP2022553129A (ja) | ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用 | |
| JP7698635B2 (ja) | 抗幹細胞因子抗体及びその使用方法 | |
| TW202216763A (zh) | 治療心血管疾病之方法 | |
| JP2017501182A5 (enExample) | ||
| JP2018517667A5 (enExample) | ||
| TWI825687B (zh) | 抗ｃｘｃｒ２抗體及其用途 | |
| US20240287169A1 (en) | Methods of use of anti-il-2 antibodies | |
| US20240279329A1 (en) | Methods of use of anti-il-2 antibodies | |
| TW202537974A (zh) | Ｔｒｇｖ９結合蛋白及其醫藥用途 | |
| CN120225557A (zh) | 特异于跨膜激活物和caml相互作用物(taci)的抗原结合蛋白 |